SYMTUZA (Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate) Patent Expiration, LOE Window & CMS Spending
SYMTUZA (Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate) by Johnson & Johnson: FDA Orange Book core substance LOE 2032-10-06 (last listed 2038-07-19), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N210455 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2032-10-06 |
| Last Listed Patent or Exclusivity Date | 2038-07-19 |
| Orange Book Patents (*PED Extensions) | 13 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.